



October 2, 2024

Applauding the Passage of H.R. 3884, *Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023*

[The Sickle Cell Disease Partnership](#) applauds the members of the U.S. House of Representatives for unanimously passing [H.R. 3884](#), *Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023* on September 23, 2024.

This bipartisan legislation, sponsored by Representatives Burgess (R-TX), Davis (D-IL), Carter (R-GA), and Lee (D-CA), is integral to continuing to improve access to care and treatment for individuals with Sickle Cell Disease (SCD) – a rare, genetic blood disorder that disproportionately impacts Black Americans and Hispanic Americans. The House action to pass this legislation during National Sickle Cell Awareness Month is an important step forward in this bipartisan SCD legislation being enacted.

This legislation reauthorizes the critically important Health Resources and Services Administration (HRSA) Sickle Cell Disease Treatment Demonstration Program (SCDTDP) through 2028. SCDTDP is a HHS grant program administered by the Health Resources and Services Administration that helps to: (1) increase the number of clinicians knowledgeable about SCD care; (2) improve the quality of care provided to individuals with SCD; (3) improve care coordination with other providers; and (4) develop best practices for coordination of services during pediatric to adult transition. Since its inception, the treatment centers involved in the SCDTDP have made progress in improving SCD care across the nation.

The Partnership also recognizes and applauds the bipartisan leadership of Senators Scott (R-SC) and Booker (D-NJ) in their championing of companion legislation in the U.S. Senate, [S. 1852](#), *Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023*. The Partnership looks forward to continuing to work with members of the House and Senate to as this important legislation continues to advance through the legislative process so it can be enacted in a timely manner.

About the Sickle Cell Disease Partnership

The Partnership is a public policy and advocacy alliance of more than a dozen healthcare and SCD organizations working together to advance federal policies to improve the lives of Americans with SCD. For more information, please visit www.SickleCellPartnership.org. You may also email the advisors to the Partnership, Josh.Trent@LeavittPartners.com, Elizabeth.Hassett@LeavittPartners.com, and Clay.Alspach@LeavittPartners.com.